A detailed history of Advisor Group Holdings, Inc. transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 33,251 shares of CABA stock, worth $89,112. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,251
Previous 33,548 0.89%
Holding current value
$89,112
Previous $250,000 37.6%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$3.94 - $8.24 $1,170 - $2,447
-297 Reduced 0.89%
33,251 $156,000
Q2 2024

Aug 13, 2024

BUY
$7.22 - $18.82 $873 - $2,277
121 Added 0.36%
33,548 $250,000
Q1 2024

May 10, 2024

BUY
$16.79 - $25.38 $96,492 - $145,858
5,747 Added 20.76%
33,427 $570,000
Q4 2023

Feb 12, 2024

SELL
$12.21 - $23.36 $240,414 - $459,958
-19,690 Reduced 41.57%
27,680 $628,000
Q3 2023

Nov 13, 2023

BUY
$11.84 - $18.65 $510,623 - $804,318
43,127 Added 1016.43%
47,370 $720,000
Q2 2023

Aug 10, 2023

SELL
$7.65 - $13.95 $18,344 - $33,452
-2,398 Reduced 36.11%
4,243 $54,000
Q1 2023

May 12, 2023

SELL
$7.08 - $12.62 $17,692 - $31,537
-2,499 Reduced 27.34%
6,641 $54,000
Q4 2022

Feb 10, 2023

BUY
$0.64 - $9.3 $4,221 - $61,342
6,596 Added 259.28%
9,140 $84,000
Q3 2022

Nov 14, 2022

SELL
$0.63 - $2.05 $2,520 - $8,200
-4,000 Reduced 61.12%
2,544 $2,000
Q2 2022

Aug 10, 2022

SELL
$0.99 - $2.11 $990 - $2,110
-1,000 Reduced 13.26%
6,544 $7,000
Q1 2022

May 04, 2022

SELL
$1.68 - $3.92 $3,118 - $7,275
-1,856 Reduced 19.74%
7,544 $15,000
Q3 2021

Nov 05, 2021

SELL
$7.0 - $12.5 $11,200 - $20,000
-1,600 Reduced 14.55%
9,400 $114,000
Q2 2021

Aug 02, 2021

BUY
$7.2 - $11.73 $77,040 - $125,511
10,700 Added 3566.67%
11,000 $95,000
Q1 2021

May 13, 2021

BUY
$10.39 - $14.53 $3,117 - $4,359
300 New
300 $3,000

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $77.8M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.